Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Hilton Lac-Leamy

Nov 05, 2019 7:30 AM - Nov 06, 2019 3:15 PM

3 Boulevard du Casino, Gatineau, QC J8Y 6X4, Canada

DIA Annual Canadian Meeting

Session 7 Track A: Implementation and Enforcement Approach for the Plain Language Labeling Regulations for Over-The-Counter (OTC) Drugs

Session Chair(s)

Kristin  Willemsen, MS

Kristin Willemsen, MS

Vice President, Scientific & Regulatory Affairs

Food, Health & Consumer Products of Canada, Canada

Robin  Churchill, PhD, MSc

Robin Churchill, PhD, MSc

Director

Health Canada, Canada

It is crunch time. Sponsors of over-the-counter (OTC) drugs are diligently working to adapt over 2,000 marketed DINs and over ten thousand labels to adapt the Drug Facts Table and comply with the Plain Language Labelling Regulations before June 2021. This year, Health Canada has been receiving a record-breaking number of PLL related submissions in preparation for this compliance date. There is no time to waste for both industry and government. Gain tactical advice from Health Canada reviewers to help improve OTC PLL submissions, review outcomes and predictability. Learn how Health Canada applies a risk-based approach to compliance and enforcement by triaging complaints based on factors, identify priorities for enforcement, and determine risks to health in order to apply the enforcement tools to mitigate risks.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Gain an appreciation for how Health Canada is managing OTC PLL submission volumes and review performance
  • Recognize tactical tips and best practices about how to effectively prepare for and navigate the OTC PLL label review process
  • Understand Health Canada’s overall approach to risk-based compliance and enforcement for OTC PLL

Speaker(s)

Jason  DiMuzio, MS

Speaker

Jason DiMuzio, MS

Health Canada, Canada

Label Review Coordinator, Non-Prescription Drugs Evaluation Division

Representative Invited

Speaker

Representative Invited

Health Canada, Canada

Kristin  Willemsen, MS

Industry Perspectives on OTC PLL Implementation

Kristin Willemsen, MS

Food, Health & Consumer Products of Canada, Canada

Vice President, Scientific & Regulatory Affairs

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.